Thrombomodulin and GFC levels in Legg–Calve–Perthes disease

References

• Caterall A. Legg-Calve-Perthes disease. Instr Course Lect 1989; 38: 297–303.
   PubMedGoogle Scholar
• Catterall A. The natural history of Perthes' disease. J Bone JointSurg Br 1971; 53: 37–53.
   Google Scholar
• Thompson GH, Price CT, Roy D, Meehan PL, Richards BS. Legg-Calve-Perthes disease: current concepts. Instr Course Lect 2002; 51: 367–384.
   PubMedGoogle Scholar
• Thompson GH, Salter RB. Legg-Calve-Perthes disease. Current concepts and controversies. Orthop Clin North Am 1987; 18: 617–35.
   PubMed Web of Science ®Google Scholar
• Dilley A, Hooper WC, Austin H et al. The beta fibrinogen gene G-455-A polymorphism is a risk factor for Legg-Perthes disease. J Thromb Haemost 2003; 1: 2317–2321.
   PubMed Web of Science ®Google Scholar
• Ferguson AB, Jr. Segmental vascular changes in the femoral headin children and adults. Clin Orthop 1985; 200: 291–298.
   PubMedGoogle Scholar
• Launder WJ, Hungerford DS, Jones LH. Hemodynamics of the femoral head. J Bone Joint Surg Am 1981; 63: 442–448.
   PubMed Web of Science ®Google Scholar
• Pavlova MN, Beliaeva AA, Mavyev BO. Vascular and microscopicchanges in hip joint tissues in Perthes' disease. Arkh Patol 1986; 48: 57–62.
   PubMed Web of Science ®Google Scholar
• Mata SG, Aicua EA, Ovejero AH, Grande MM. Legg-Calve-Perthes disease and passive smoking. J Pediatr Orthop 2000; 20: 326–330.
   PubMed Web of Science ®Google Scholar
• Wingstrand H. Significance of synovitis in Legg-Calve-Perthes disease. J Pediatr Orthop B 1999; 8: 156–160.
   PubMed Web of Science ®Google Scholar
• Eldridge J, Dilley A, Austin H et al. The role of protein C, proteinS, and resistance to activated protein C in Legg-Perthes disease. Pediatrics 2001; 107: 1329–1334.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Freiberg RA, Wang P. Role of thrombosis in osteonecrosis. Curr Hematol Rep 2003; 2: 417–422.
   PubMedGoogle Scholar
• Glueck CJ, Crawford A, Roy D, Freiberg R, Glueck H, Stroop D. Association of antithrombotic factor deficiencies and hypofibrino-lysis with Legg-Perthes disease. J Bone Joint Surg Am 1996; 78: 3–13.
   PubMedGoogle Scholar
• Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne BS. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 1993; 44: 243–248.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Freiberg R, Tracy T, Stroop D, Wang P. Thrombophilia and hypofibrinolysis: pathophysiologies of osteo-necrosis. Clin Orthop 1997; 334: 43–56.
   PubMedGoogle Scholar
• Hayek S, Kenet G, Lubetsky A, Rosenberg N, Gitel S, Wientroub S. Does thrombophilia play an aetiological role in Legg-Calve-Perthes disease? J Bone Joint Surg Br 1999; 81: 686–690.
   PubMedGoogle Scholar
• Hresko MT, McDougall PA, Gorlin JB, Vamvakas EC, Kasser JR, Neufeld EJ. Prospective reevaluation of the association between thrombotic diathesis and legg-perthes disease. J Bone Joint Surg Am 2002; 84A: 1613–1618.
   Web of Science ®Google Scholar
• Liesner RJ. Does thrombophilia cause Perthes' disease in children? J Bone Joint Surg Br 1999; 81: 565–566.
   PubMedGoogle Scholar
• Thomas DP, Morgan G, Tayton K. Perthes' disease and the relevance of thrombophilia. J Bone Joint Surg Br 1999; 81: 691–695.
   PubMedGoogle Scholar
• Glueck CJ, Freiberg RA, Crawford A et al. Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease. Clin Orthop 1998; 352: 159–167.
   PubMed Web of Science ®Google Scholar
• Koo KH, Song HR, Ha YC et al. Role of thrombotic and fibrinolytic disorders in the etiology of Perthes' disease. Clin Orthop 2002; 399: 162–167.
   PubMedGoogle Scholar
• Ozatli D, Sayinalp N, Buyukasik Y et al. Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behcet's disease: evidence of a prethrombotic state. Rheumatol Int 2002; 21: 137–140.
   PubMed Web of Science ®Google Scholar
• Atalar E, Acil T, Aytemir K et al. Diminished global fibrinolytic capacity in patients with mitral valve prolapse is associated with transient ischemic attacks. Clin App/ Thromb Hemost 2002; 8: 41–44.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002; 87: 3871–3875.
   PubMed Web of Science ®Google Scholar
• Yurdakok M, Korkmaz A, Kirazli S, Aygun C, Yigit S. Global fibrinolytic capacity in early respiratory distress syndrome: a pilot study. Am J Hematol 2002; 69: 255–257.
   PubMed Web of Science ®Google Scholar
• Van de Wouver M, Conway EM. Novel functions of thrombo-modulin in inflammation Crit Care Med 2004; 32: 254–261.
   Google Scholar
• Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9: 946–955.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Lee .J.J, Chung JY, Moon ES, Song EK, Seo HY. Deformity of the femoral head following vascular infarct in piglets. Acta Orthop 2006; 77: 33–38.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Kim MS, Moon ES, Song EK, Yoon TR, Cho SB. Developmental pattern of femoral shortening following devascu-larization of the capital femoral epiphysis in piglets. J Pediatr Orthop 2005; 25: 300–304.
   PubMed Web of Science ®Google Scholar
• Gregosiewicz A, Okonski M, Stolecka D, Kandzierski G, Szponar M. Ischemia of the femoral head in Perthes' disease: is the cause intra- or extravascular? J Pediatr Orthop 1989; 9: 160–162.
   Google Scholar
• Posan E, Szepesi K, Gaspar L et al. Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral head. Blood Coag Fibrinol 2003; 14: 243–248.
   PubMed Web of Science ®Google Scholar
• Aksoy MC, Aksoy DY, Haznedaroglu IC, Sayinalp N, Kirazli S, Alpaslan M. Enhanced tissue factor pathway inhibitor response as a defense mechanism against local microvascular events of Legg-Calve-Perthes disease. Pediatr Hematol Oncol 2005; 22: 391–399.
   PubMed Web of Science ®Google Scholar
• Kato H. Regulation of functions of vascular wall cells by tissue factorpathway inhibitor. Arterioscler Thromb Vase Biol 2002; 22: 539–548.
   PubMed Web of Science ®Google Scholar
• Lupu C, Kruithof EKO, Kakkar VV, Lupu F. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons. Thromb Haemost 1999; 82: 1652–1658.
   PubMed Web of Science ®Google Scholar
• Esmon T. Regulation of blood coagulation. Biochem biophys Acta 2000; 1477: 349–360.
   PubMed Web of Science ®Google Scholar
• Van de Wouwer M, Conway EM. Novel functions of thrombomodulin in inflammation Grit Care Med 2004; 32: 254–260.
   PubMed Web of Science ®Google Scholar
• Hassan A, Hunt BJ, O'Sullivan M et al. Markers of endothelial dysfunction in lacunar infarction and ischaemicluekoaraiosis. Brain 2003; 126: 424–432.
   PubMed Web of Science ®Google Scholar
• Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 2000; 35: 1926–1931.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Two-way interaction between inflammation and coagulation. Trends Cardivasc Med 2005; 15: 254–258.
   PubMed Web of Science ®Google Scholar
• Nesheim MN. Thrombin and fibrinolysis. Chest 2003; 124( Suppl): 33-39S.
   Web of Science ®Google Scholar